SynthesisPediatric cardiology2026
Outcomes of Primary Vs. Staged Repair in 4628 Neonates with Symptomatic Tetralogy of Fallot: A Systematic Review and Meta-analysis.
Synthesis in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are two strategies to treat neonates with symptomatic tetralogy of Fallot (TOF), primary repair (PR) and staged repair (SR). There is still a debate on the best surgical strategy. We aim to compare PR and SR regarding mortality and comorbidities. We executed a systematic search on PubMed, Embase, Scopus, Web of Science (WOS), and Cochrane Central till January 10, 2025. We included studies with neonates with symptomatic TOF who received an intervention within the first 30 days of life, either with SR or PR. The primary outcomes were in-hospital, 30-day, and 2-year mortality rates. We used Review Manager to calculate the risk ratio (RR) and its 95% confidence interval (CI) for categorical variables and the mean difference (MD) and its 95% CI for continuous outcomes. A P-value less than 0.05 was considered significant. The I-squared test was used to assess heterogeneity. The RRs of mortality at 30 days and 2 years were comparable between both approaches (RR = 0.53; [95% CI = 0.22-1.27], P = 0.15) and (RR = 1.22; [95% CI = 0.0.99-1.51], P = 0.07) respectively. While the length of hospital stay (MD = 18.47 days; [95% CI = 10.87-26.08], P < 0.00001), length of intensive care unit stay (MD = 4.18 days; [95% CI = 3.12-5.23], P < 0.00001), and cardiopulmonary bypass time (MD = 46,47 day; [95% CI = 37.71-55.24], P < 0.00001), all were longer with SR. PR and SR strategies are equivalent regarding short- and long-term mortality in neonates with symptomatic TOF.
Indexed as
Identifiers
40659877What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.